PDS Biotechnology Corp
PDSB1.095USD
+0.005+0.46%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
49.76MCap. mercado
PérdidaP/E TTM
Más Datos de PDS Biotechnology Corp Compañía
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Información de la empresa
Símbolo de cotizaciónPDSB
Nombre de la empresaPDS Biotechnology Corp
Fecha de salida a bolsaOct 01, 2015
Director ejecutivoDr. Frank Bedu-Addo, Ph.D.
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 01
Dirección303A College Road East
CiudadPRINCETON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal08540
Teléfono18002083343
Sitio Webhttps://www.pdsbiotech.com
Símbolo de cotizaciónPDSB
Fecha de salida a bolsaOct 01, 2015
Director ejecutivoDr. Frank Bedu-Addo, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Stephan Toutain
Mr. Stephan Toutain
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 26 de jul
Actualizado: sáb., 26 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Armistice Capital LLC
9.67%
The Vanguard Group, Inc.
3.30%
Bedu-Addo (Frank)
1.51%
BlackRock Institutional Trust Company, N.A.
1.05%
Sykes (Richard)
0.97%
Other
83.49%
Accionistas
Accionistas
Proporción
Armistice Capital LLC
9.67%
The Vanguard Group, Inc.
3.30%
Bedu-Addo (Frank)
1.51%
BlackRock Institutional Trust Company, N.A.
1.05%
Sykes (Richard)
0.97%
Other
83.49%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
9.80%
Investment Advisor
6.01%
Individual Investor
3.09%
Investment Advisor/Hedge Fund
1.54%
Research Firm
0.71%
Pension Fund
0.04%
Bank and Trust
0.01%
Other
78.80%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
187
9.67M
21.15%
+1.28M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
2023Q2
183
9.26M
30.03%
-1.73M
2023Q1
149
11.76M
39.00%
-275.25K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Armistice Capital LLC
4.42M
9.67%
+4.42M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.51M
3.3%
+4.41K
+0.29%
Mar 31, 2025
Bedu-Addo (Frank)
690.87K
1.51%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
480.97K
1.05%
-4.48K
-0.92%
Mar 31, 2025
Sykes (Richard)
445.11K
0.97%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
437.88K
0.96%
+20.66K
+4.95%
Mar 31, 2025
William Blair & Company, L.L.C. (Research)
257.20K
0.56%
+99.70K
+63.30%
Mar 31, 2025
UBS Financial Services, Inc.
245.33K
0.54%
+221.67K
+936.97%
Mar 31, 2025
State Street Global Advisors (US)
133.33K
0.29%
--
--
Mar 31, 2025
Conn (Gregory L Ph.D.)
123.59K
0.27%
--
--
Apr 17, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Global X Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.01%
DFA Dimensional US Core Equity Market ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
